{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:05:57Z","timestamp":1785128757761,"version":"3.55.0"},"reference-count":60,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The spread of extended-spectrum \u03b2-lactamase (ESBL)-producing <ns4:italic>Enterobacteriaceae<\/ns4:italic> (ESBL-PE) has dramatically increased worldwide, and this \u201cevolving crisis\u201d is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between \u201cScylla and Charybdis\u201d: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization\u2019s warning against a \u201cpost antibiotic era\u201d, health-care providers are at a critical standpoint to find a \u201cbalance\u201d between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.<\/ns4:p>","DOI":"10.12688\/f1000research.14822.1","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T06:45:17Z","timestamp":1535525117000},"page":"1347","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Treatment of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?"],"prefix":"10.12688","volume":"7","author":[{"given":"Zoi Dorothea","family":"Pana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-1081","authenticated-orcid":false,"given":"Theoklis","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1335-46","DOI":"10.3390\/ph6111335","article-title":"A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.","volume":"6","author":"I Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e0171216","DOI":"10.1371\/journal.pone.0171216","article-title":"Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis.","volume":"12","author":"M Flokas","year":"2017","journal-title":"PLoS One."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1226-32","DOI":"10.1086\/507962","article-title":"Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.","volume":"27","author":"S Lee","year":"2006","journal-title":"Infect Control Hosp Epidemiol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"33-41","DOI":"10.1016\/j.jhin.2015.10.001","article-title":"Impact of infection with extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs.","volume":"92","author":"J Maslikowska","year":"2016","journal-title":"J Hosp Infect."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1-16","DOI":"10.3109\/1040841X.2013.875515","article-title":"Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective.","volume":"42","author":"L Biehl","year":"2016","journal-title":"Crit Rev Microbiol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"660-7","DOI":"10.1017\/ice.2018.63","article-title":"Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.","volume":"39","author":"O Scheuerman","year":"2018","journal-title":"Infect Control Hosp Epidemiol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"4943-60","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future.","volume":"55","author":"K Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"583-94","DOI":"10.1097\/QCO.0000000000000314","article-title":"The management of multidrug-resistant Enterobacteriaceae.","volume":"29","author":"M Bassetti","year":"2016","journal-title":"Curr Opin Infect Dis."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1319-25","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia.","volume":"60","author":"P Tamma","year":"2015","journal-title":"Clin Infect Dis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"2043-55","DOI":"10.1093\/jac\/dku111","article-title":"The risk of seizures among the carbapenems: a meta-analysis.","volume":"69","author":"J Cannon","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1672-80","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.","volume":"71","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"205-18","DOI":"10.1080\/14787210.2018.1436966","article-title":"Management of infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: current evidence and future prospects.","volume":"16","author":"C Sheu","year":"2018","journal-title":"Expert Rev Anti Infect Ther."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2793-803","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis.","volume":"67","author":"K Vardakas","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"115-21","DOI":"10.1007\/s00277-011-1247-7","article-title":"Risk factors for infection and treatment outcome of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.","volume":"91","author":"C Kang","year":"2012","journal-title":"Ann Hematol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"167-74","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.","volume":"54","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.","volume":"4","author":"P Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"981-5","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.","volume":"36","author":"H Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"4159-69","DOI":"10.1128\/AAC.00365-16","article-title":"A Multinational, Preregistered Cohort Study of \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-\u03b2-Lactamase-Producing Enterobacteriaceae.","volume":"60","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"3402-4","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli.","volume":"57","author":"P Retamar","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.","volume":"17","author":"Y Seo","year":"2017","journal-title":"BMC Infect Dis."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e013268","DOI":"10.1136\/bmjopen-2016-013268","article-title":"Clinical efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).","volume":"7","author":"C Gudiol","year":"2017","journal-title":"BMJ Open."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"305-11","DOI":"10.1007\/s10096-017-3133-2","article-title":"Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.","volume":"37","author":"J Ko","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13613-017-0334-x","article-title":"Piperacillin-tazobactam as alternative to carbapenems for ICU patients.","volume":"7","author":"B Pilmis","year":"2017","journal-title":"Ann Intensive Care."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13063-014-0541-9","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.","volume":"16","author":"P Harris","year":"2015","journal-title":"Trials."},{"key":"ref-25","article-title":"Abstract no: O1121, The MERINO Trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin non-susceptible Escherichia coli or Klebsiella spp.: an international multi-centre open-label non-inferiority randomised controlled trial.","year":"2018","journal-title":"session Late breaker:\nClinical trials."},{"key":"ref-26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01094-17","article-title":"Use of \u03b2-Lactam\/\u03b2-Lactamase Inhibitors for Extended-Spectrum-\u03b2-Lactamase Infections: Defining the Right Patient Population.","volume":"61","author":"P Tamma","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum \u03b2-Lactamase-Producing Enterobacteriaceae Bacteremia.","volume":"3","author":"R Wang","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"56-62","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.","volume":"12","author":"K Goethaert","year":"2006","journal-title":"Clin Microbiol Infect."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"3936-42","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli.","volume":"56","author":"T Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"3442-7","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.","volume":"47","author":"G Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"488-95","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.","volume":"56","author":"N Lee","year":"2013","journal-title":"Clin Infect Dis."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"972-80","DOI":"10.1093\/cid\/cix034","article-title":"The Use of Noncarbapenem \u03b2-Lactams for the Treatment of Extended-Spectrum \u03b2-Lactamase Infections.","volume":"64","author":"P Tamma","year":"2017","journal-title":"Clin Infect Dis."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"321-47","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin.","volume":"29","author":"M Falagas","year":"2016","journal-title":"Clin Microbiol Rev."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"273-80","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Fosfomycin: Resurgence of an old companion.","volume":"22","author":"S Sastry","year":"2016","journal-title":"J Infect Chemother."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"269-85","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.","volume":"47","author":"K Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"506-15","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.","volume":"34","author":"N Roussos","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"5602-10","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.","volume":"59","author":"F Docobo-P\u00e9rez","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): Study protocol for an investigator-driven randomised controlled trial.","volume":"5","author":"C Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"100-4","DOI":"10.1159\/000449422","article-title":"Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.","volume":"62","author":"S Giancola","year":"2017","journal-title":"Chemotherapy."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"111-20","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.","volume":"34","author":"M Falagas","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"100-3","DOI":"10.1016\/j.ijantimicag.2018.03.014","article-title":"Which non-carbapenem antibiotics are active against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae?","volume":"52","author":"H Bouxom","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"ref-42","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1404813","article-title":"Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.","volume":"2018","author":"G Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"363-72","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature.","volume":"23","author":"B Grabein","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"5834-7","DOI":"10.1128\/AAC.01121-15","article-title":"In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-\u03b2-lactamase-producing Escherichia coli isolates causing bacteremia.","volume":"59","author":"M Cha","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"762-7","DOI":"10.1016\/j.jiac.2014.08.007","article-title":"Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae.","volume":"20","author":"T Ipekci","year":"2014","journal-title":"J Infect Chemother."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"156-61","DOI":"10.3904\/kjim.2016.31.1.156","article-title":"Amikacin therapy for urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli.","volume":"31","author":"S Cho","year":"2016","journal-title":"Korean J Intern Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"459-73","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.","volume":"10","author":"G Zhanel","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1501-11","DOI":"10.1517\/13543784.2015.1095180","article-title":"Plazomicin: an investigational therapy for the treatment of urinary tract infections.","volume":"24","author":"I Karaiskos","year":"2015","journal-title":"Expert Opin Investig Drugs."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"48-53","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.","volume":"66","author":"D Livermore","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"2554-63","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.","volume":"58","author":"A Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2628-31","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae.","volume":"66","author":"I Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"891-8","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.","volume":"70","author":"P Laterre","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"1380-9","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.","volume":"62","author":"J Mazuski","year":"2016","journal-title":"Clin Infect Dis."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"997-8","DOI":"10.1016\/S1473-3099(16)30265-1","article-title":"Ceftazidime-avibactam in ceftazidime-resistant infections.","volume":"16","author":"Y Carmeli","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1046-56","DOI":"10.1177\/1060028015593293","article-title":"Ceftolozane\/Tazobactam: A New Cephalosporin and \u03b2-Lactamase Inhibitor Combination.","volume":"49","author":"A Sucher","year":"2015","journal-title":"Ann Pharmacother."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"231-42","DOI":"10.1007\/s40265-015-0524-5","article-title":"Ceftolozane\/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.","volume":"76","author":"L Scott","year":"2016","journal-title":"Drugs."},{"key":"ref-58","article-title":"ZerbaxaTM (ceftolozane and tazobactam) for injection fiuUpihzc"},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1462-71","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).","volume":"60","author":"J Solomkin","year":"2015","journal-title":"Clin Infect Dis."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"5350-7","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.","volume":"58","author":"C Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/S0140-6736(15)00263-9","article-title":"Ceftolozane-tazobactam versus levofloxacin in urinary tract infection - Authors' reply.","volume":"386","author":"F Wagenlehner","year":"2015","journal-title":"Lancet."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T15:32:39Z","timestamp":1553873559000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":60,"URL":"https:\/\/doi.org\/10.12688\/f1000research.14822.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.16132.r37545","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.16132.r37546","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.16132.r37545, Jean-Ralph Zahar, Infection Control Unit, H\u00f4pital Avicenne (AP-HP), Bobigny, France, 29 Aug 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1#referee-response-37545","order":0,"name":"referee-response-37545","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.16132.r37546, Patrice Nordmann, Medical and Molecular Microbiology, Faculty of Science and Medicine, National Reference Center for Emerging Antibiotic Resisance and Foreign Reserach Unit (INSERM, France) University of Fribourg, Fribourg, Switzerland, 29 Aug 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1347\/v1#referee-response-37546","order":1,"name":"referee-response-37546","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}